• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Autologous stem-cell transplantation benefits high-risk patients with non-Hodgkin’s lymphoma

bys25qthea
October 30, 2013
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Autologous stem-cell transplantation improved progression-free survival in patients with high-intermediate-risk and high-risk disease, but did not show improvement in overall survival.

2. Retrospective subgroup analysis suggests that early transplantation may provide greater benefit to patients with high-risk disease than patients with high-intermediate-risk disease.

Evidence Rating Level: 2 (Good)

Study Rundown: This study suggests a survival benefit of early autologous stem-cell transplantation in intermediate-high-risk and high-risk patients with non-Hodgkin’s lymphoma, categorized by the International Prognostic Index (IPI) score. Standard therapy for patients with non-Hodgkin’s lymphoma generally proceeds with the regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), often with the addition of the anti-B-cell monoclonal antibody, rituximab (R-CHOP) in patients with CD20+ disease. The role for transplantation once initial remission has been achieved remains controversial, though some studies suggest a benefit in patients with high-intermediate-risk and high-risk disease. This study specifically enrolled patients with these higher-risk IPI scores to evaluate this question and found that transplantation improved progression-free survival for both high-intermediate-risk and high-risk patients. Transplantation appeared to have a greater benefit in high-risk patients, reflected in both progression-free survival and overall survival.  However, this finding was identified in retrospective subgroup analysis. Further studies should be powered to elucidate this correlation and determine other mechanisms of matching optimal therapies to disease subtype.

Click to read the study, published today in NEJM

Click to read an accompanying editorial in NEJM

RELATED REPORTS

Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma

#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers

#VisualAbstract: Adolescents had an increased risk of all-cause mortality over younger children with Hodgkin lymphoma

Background Reading: NCCN Clinical Practice Guidelines: Non-Hodgkin’s Lymphomas

In-Depth [randomized, controlled trial]: This study examined the role of early autologous stem-cell transplantation in the treatment of patients with non-Hodgkin’s lymphoma, classified as either high-intermediate-risk or high-risk by IPI score. The authors recruited a total of 397 patients with biopsy-confirmed non-Hodgkin’s lymphomas. They excluded patients with lymphoblastic, transformed, or mantle-cell lymphomas.  Patients were then evaluated by IPI score and determined to be high-intermediate-risk or high-risk. Of the total group, 253 eligible patients underwent induction therapy consisting of 5 weeks of CHOP or R-CHOP depending on the CD20 status of the cancer. Once induction was achieved, patients were randomized to receive either three additional cycles of induction chemotherapy (control group) or one cycle of chemotherapy and autologous stem-cell transplantation (transplantation group). The 2-year progression-free survival rates in the transplantation and control groups were 69% and 55%, respectively (hazard ratio in the control vs. transplantation group, 1.72; 95%CI: 1.18 to 2.51; P=0.005). The 2-year overall survival rate did not differ significantly between groups. However, subsequent, exploratory subgroup analysis showed a significant interaction between risk level and overall survival. In high-risk patients, the 2-year overall survival rate was greater in the transplantation group compared to the control group (82% vs. 64%).

By Akira Shishido, MD and Adrienne Chueng

More from this author: Pneumocystis linked to sudden infant deaths, Continuous infusion of beta-lactams may be superior to bolus therapy, Novel antiviral drug reduces influenza viral load, Three months of antibiotics appear to effectively treat early-onset spinal implant infections

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

 

 

Tags: autologous stem cell transplantationlymphomastem cells
Previous Post

Nab-paclitaxel plus gemcitabine improves survival in metastatic pancreatic cancer

Next Post

Single-site robotic cholecystectomy is safe, but technically challenging

RelatedReports

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma
Chronic Disease

Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma

June 29, 2022
#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers
StudyGraphics

#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers

April 12, 2022
#VisualAbstract: Adolescents had an increased risk of all-cause mortality over younger children with Hodgkin lymphoma
StudyGraphics

#VisualAbstract: Adolescents had an increased risk of all-cause mortality over younger children with Hodgkin lymphoma

January 20, 2022
#VisualAbstract: Addition of itacitinib to corticosteroids did not show clinical benefit over placebo in initial treatment of acute graft-versus-host disease
StudyGraphics

#VisualAbstract: Addition of itacitinib to corticosteroids did not show clinical benefit over placebo in initial treatment of acute graft-versus-host disease

January 6, 2022
Next Post
Single-site robotic cholecystectomy is safe, but technically challenging

Single-site robotic cholecystectomy is safe, but technically challenging

Blindness and visual impairment decreasing worldwide

Saccadic eye movements predictive of surgical resident fatigue

Novel cytokines found elevated in diabetic retinopathy patients

Intra-arterial thrombolysis in central retinal artery occlusion can benefit some patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
  • Cognitive behavioral therapy efficacious for treatment of comorbid posttraumatic headache and posttraumatic stress disorder symptoms among US veterans
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.